Document is current
Any future updates will be listed below
-
Authors
Qiu, Hui
Wu, Tingting
Diao, Lei
Yu, Nianda
Chen, Hong
Peng, Xi
Jie Huang,
Xie, Jinlian
Wu, Qian
Yang, Shuang
Yang, Xiaoyan
Zeng, Long
Pei, Qi
Guo, Chengxian
Yang, Guoping
-
Clinical Trials BETA
Clinical trials referenced in this document:
chictr2500103582 at Chinese Clinical Trial RegistryDocuments that mention this clinical trial
Pharmacokinetics, safety, and tolerability of nacubactam (OP0595) after intravenous infusion: a randomized, double-blind, placebo-controlled phase I clinical trial in healthy Chinese male subjects
https://doi.org/10.1007/s10238-025-01951-1
-
Funding
Funding for this research was provided by:
the National Natural Science Foundation of China (No.82474009)
the Hunan Provincial Natural Science Foundation of China (No. 2023JJ60513)
- License Information
-
More Information
Article History
Received: 1 September 2025
Accepted: 19 October 2025
First Online: 2 December 2025
Declarations
:
: Lei Diao and Nianda Yu are the employees of Shanghai Fosun Pharmaceutical Development Co., Ltd. Hong Chen and Xi Peng are the employees of Fobeni Healthcom Pharmaceutical Jiangsu Co., Ltd. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
: The study protocol was registered with the Chinese Clinical Trial Registry (Registration No. ChiCTR2500103582) and approved by the Ethics Committee of the Third Xiangya Hospital, Central South University.
